Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 3:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 285 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sweating Clear all
Active, not recruiting Phase 3 Interventional

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

NCT06921850
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
9 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Phoenix, Arizona • Roseville, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 12, 2026, 3:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

NCT04772885
View directory record Official record
Conditions
Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions
KT-474/Placebo, KT-474
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Sep 12, 2026, 3:52 PM EDT
Not yet recruiting Not applicable Interventional

Mediterranean Dietary Intervention for HS

NCT07800416
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Mediterranean Diet Counseling, Mediterranean Food Support
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 12, 2026, 3:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Sunscreen During Exercise Under Conditions of Profuse Sweating

NCT02842268
View directory record Official record
Conditions
Sunscreening Agent
Interventions
BAY987517
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 12, 2026, 3:52 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis

NCT02479139
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Vehicle, ANT-1207
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 70 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Hialeah, Florida • Miami, Florida • Pinellas Park, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Sep 12, 2026, 3:52 PM EDT
Completed Phase 3 Interventional

Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy

NCT00003739
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 12, 2026, 3:52 PM EDT
Completed Phase 3 Interventional Results available

Study of Glycopyrronium in Axillary Hyperhydrosis

NCT02530281
View directory record Official record
Conditions
Hyperhidrosis
Interventions
glycopyrronium Topical Wipes, Vehicle
Drug · Other
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
9 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Mobile, Alabama • Encinitas, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Sep 12, 2026, 3:52 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis

NCT02565732
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Botulinum toxin type A, Placebo comparator
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Sep 12, 2026, 3:52 PM EDT
Completed Phase 1 Interventional

Hyperhidrosis, Developing a Treatment Approach Aims 1 & 2

NCT03416348
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Aluminum Chloride 20% (deodorant), Alcohol
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Sep 12, 2026, 3:52 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients

NCT02421172
View directory record Official record
Conditions
Hidradenitis Suppurativa (Acne Inversa)
Interventions
CJM112, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Los Angeles, California • Ormond Beach, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Sep 12, 2026, 3:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Non-Interventional Study To Assess Sweating

NCT02552199
View directory record Official record
Conditions
Hyperhidrosis
Interventions
gravimetric
Other
Lead sponsor
Botanix Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Carpinteria, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 12, 2026, 3:52 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis

NCT02563899
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Umeclidinium, Vehicle
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Raleigh, North Carolina • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 12, 2026, 3:52 PM EDT
Completed Early Phase 1 Interventional

Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa

NCT03099980
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
secukinumab
Biological
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Sep 12, 2026, 3:52 PM EDT
Completed Phase 2 Interventional Results available

A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

NCT04876391
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Spesolimab 1200 mg, Spesolimab 600 mg, Placebo matching 600 mg Spesolimab, Placebo matching 1200 mg Spesolimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 12, 2026, 3:52 PM EDT
Terminated Phase 2 Interventional Results available

Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT01838499
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
MEDI8968, Saline
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Phoenix, Arizona • Bakersfield, California • Fremont, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Sep 12, 2026, 3:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

VASER Treatment of Axillary Hyperhidrosis/Bromidrosis

NCT00735293
View directory record Official record
Conditions
Axillary Hyperhidrosis
Interventions
VASER
Device
Lead sponsor
Commons Aesthetic Plastic Surgery
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2008 · Synced Sep 12, 2026, 3:52 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Feasibility Study on Radiofrequency-Based Selective Electrothermolysis to Investigate Its Effects on Human Skin

NCT05066113
View directory record Official record
Conditions
Hidradenitis Suppurativa, Healthy Volunteers
Interventions
Radiofrequency-Based treatment
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 12, 2026, 3:52 PM EDT
Recruiting Early Phase 1 Interventional

Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.

NCT06326476
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Siplizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 12, 2026, 3:52 PM EDT
Completed Phase 2 Interventional

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06046729
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Eltrekibart, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
42
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Rogers, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 12, 2026, 3:52 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

NCT05819398
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Spesolimab i.v., Spesolimab s.c., Placebo matching Spesolimab i.v., Placebo matching Spesolimab s.c.
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 12, 2026, 3:52 PM EDT
Terminated Not applicable Interventional Results available

Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa

NCT03040804
View directory record Official record
Conditions
Hidradenitis Suppurativa, Hidradenitis
Interventions
Low dose Radiotherapy
Radiation
Lead sponsor
Montefiore Medical Center
Other
Eligibility
20 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 12, 2026, 3:52 PM EDT
Completed Not applicable Interventional

Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa

NCT01063270
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Clindamycin & Rifampin, Clindamycin + Rifampin along with NdYag Laser treatment
Drug · Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
16 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 12, 2026, 3:52 PM EDT
Completed Not applicable Interventional Results available

A Bioelectric Dressing for Post De-Roofing Treatment of HS

NCT05057429
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bioelectric Dressing, Standard Gauze Dressing
Device · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 12, 2026, 3:52 PM EDT
Terminated No phase listed Observational

Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19

NCT05044780
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 12, 2026, 3:52 PM EDT